ResponderID
Genialis ResponderID™ is a biomarker discovery platform that employs a people-first framework to model underlying disease biology. The platform marries this novel approach to biomarker conceptualization with proprietary technology, validated signatures and human data. The result is biomarkers that work in real patient populations and scale across clinical settings.
ResponderID is uniquely capable of developing biomarkers for investigational drugs by modeling disease biology rather than relying on treatment response. Adhering to the FDA’s Good Machine Learning Practice guidelines and numerous international standards, our biomarkers are built to work for patients. These “just in time” biomarkers are especially well suited for helping new therapies reach the right patients who need them most.
